Company
NYSE:VNRX
VolitionRx Limited is a multi-national epigenetics company developing simple, easy-to-use, cost-effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients but also to improve their quality of life. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics. Volition's research and development activities are centered in Belgium, with additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic products to market.
89 stories · page 2 of 5
"This quarter, and subsequent to quarter end, I am proud we have executed yet another global supply agreement with a market leader in pet healthcare," said CEO Cameron Reynolds
The non-interventional study will be overseen by Dr Jérôme Benoit, the clinical director of Oncovet in Lille
“We know that screening saves lives and there is a real unmet need for lung cancer screening globally," said COO Gael Forterre
“It is another key milestone for us, as we press ahead with our aim to ensure as many veterinarians as possible can access our Nu.Q vet cancer screening test for the pets and pet owners who trust them,” said VolitionRx veterinarian diagnost
A peer-reviewed clinical study showed the Nu.Q blood test detected 76% of systemic cancers in animals
Henshall told Volition shareholders that she believes there is enormous potential for the company to revolutionize the diagnosis of life-altering diseases through its Nu.Q product portfolio
The epigenetics company had a busy quarter that saw it receive a CE Mark for its Nu.Q Netosis test in Europe and reveal new clinical studies for NETs in the US
“Cancer patients have a weakened immune system and have a 10 times higher likelihood of developing sepsis and are also more likely to die if they develop it,” VolitionRx chief scientific officer Dr Jake Micallef said
“DXOCRO will spearhead both our clinical product development and our regulatory program in the United States, and seek to establish clinical utility for our Nu.Q products,” said Sharon Ballesteros, US head of quality and development process
The company said the loan from Namur Invest will fund an early access program for Volition's Nu.Q product portfolio at key sites across the EU, UK, and the United States
Both deals will make use of Volition's Nu.Q technology, which can specifically recognize and target epigenetically modified nucleosomes
The gross proceeds to Volition from the offering, before deducting the underwriting commissions and other estimated offering expenses payable by Volition, are expected to be $6 million
The company published a poster presentation entitled "Evaluation and comparison of NETosis biomarkers in sepsis and COVID-19 patients" that showcased the correlation reported between the Nu.Q NETs level and the currently used SOFA score
"NETosis has become a huge focus for medics in recent years, given elevated levels of NETs are associated with poor patient outcomes in a range of diseases, such as COVID-19, but also including sepsis and cancer,” Jake Micallef, chief scien
The Austin, Texas-based epigenetics company said it had cash and cash equivalents of around $23.7 million as of March 31, 2022, compared with $20.6 million at the end of December 2021
SAGE is now actively marketing the test and will be processing samples and providing test results from its centralized lab with immediate effect
Ballesteros has more than 20 years of experience within the in-vitro diagnostics industry with senior roles at companies such as Siemens Health Diagnostics and Thermo Fisher
"Volition Veterinary is an exciting, fast-moving part of our business with clear potential to generate significant revenue for the company, initially under our agreements with Heska and SAGE Healthcare, through both milestone payments and o
Heska will receive the worldwide rights to sell the test while VolitionRX will get a $10 million upfront payment on signing and up to $18 million based upon near to mid-term milestones
The studies found that Volition’s flagship Nu.Q assays, when used with the Fecal Immunochemical Test (FIT), can detect colorectal cancer and all high-risk advanced adenomas in symptomatic patients, reducing unnecessary colonoscopies
